| Title |
Long-Acting Injectable Hormonal Dosage Forms for Contraception
|
|---|---|
| Published in |
Pharmaceutical Research, April 2015
|
| DOI | 10.1007/s11095-015-1686-2 |
| Pubmed ID | |
| Authors |
Linfeng Wu, Dileep R. Janagam, Timothy D. Mandrell, James R. Johnson, Tao L. Lowe |
| Abstract |
Although great efforts have been made to develop long-acting injectable hormonal contraceptives for more than four decades, few long-acting injectable contraceptives have reached the pharmaceutical market or even entered clinical trials. On the other hand, in clinical practice there is an urgent need for injectable long-acting reversible contraceptives which can provide contraceptive protection for more than 3 months after one single injection. Availability of such products will offer great flexibility to women and resolve certain continuation issues currently occurring in clinics. Herein, we reviewed the strategies exploited in the past to develop injectable hormonal contraceptive dosages including drug microcrystal suspensions, drug-loaded microsphere suspensions and in situ forming depot systems for long-term contraception and discussed the potential solutions for remaining issues met in the previous development. |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 2% |
| Unknown | 63 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 16% |
| Student > Master | 8 | 13% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Bachelor | 4 | 6% |
| Professor | 3 | 5% |
| Other | 12 | 19% |
| Unknown | 20 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 25% |
| Medicine and Dentistry | 5 | 8% |
| Chemistry | 5 | 8% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Nursing and Health Professions | 2 | 3% |
| Other | 11 | 17% |
| Unknown | 21 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2022.
All research outputs
#2,182,115
of 23,262,131 outputs
Outputs from Pharmaceutical Research
#95
of 2,883 outputs
Outputs of similar age
#29,312
of 266,483 outputs
Outputs of similar age from Pharmaceutical Research
#2
of 29 outputs
Altmetric has tracked 23,262,131 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,883 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,483 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.